Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05088239 Completed - Breast Cancer Clinical Trials

Deep Inferior Epigastric Artery Flap for Breast Reconstruction

Start date: July 1, 2011
Study type: Observational

Background: There is no consensus on the duration of prophylactic antibiotics for autologous breast reconstruction after mastectomy. We try to standardize prophylactic antibiotics use during breast reconstruction with deep inferior epigastric perforator flap following mastectomy. Methods: This retrospective case series involved 108 patients who underwent immediate breast reconstruction with deep inferior epigastric perforator flap in Ditmanson Medical Foundation Chia-Yi Christian Hospital between 2012 and 2019. Patients were divided into three groups based on prophylactic antibiotic duration: 1 day, 3 days and >7 days for patients with drains Data were analyzed between January and April, 2021.

NCT ID: NCT05054166 Completed - Breast Cancer Clinical Trials

Efficacy of Everolimus-containing Chemotherapy in HER2- mBC Patients With PI3K/AKT/mTOR Mutations Study

Start date: May 1, 2021
Study type: Observational

The study aimed to investigate the efficacy of the everolimus-containing chemotherapy in metastatic breast cancer patients with PI3K/AKT/mTOR mutations.14 cases of HER2- metastatic breast cancer patients with PI3K/AKT/mTOR mutations treated with everolimus-containing chemotherapy were retrospectively analyzed.The genetic profile in PI3K/AKT/mTOR pathway was studied.

NCT ID: NCT05053841 Completed - Breast Cancer Clinical Trials

Implication of Metformin Plus Aromatase Inhibitor in Obese Postmenopausal Breast Cancer Women

Start date: February 2014
Phase: Phase 2
Study type: Interventional

Metformin is an anti-diabetic oral hypoglycemic agent that considered the gold standard therapy for the treatment of type 2 diabetes. Retrospective analyses show that metformin can offer therapeutic benefits to patients with several forms of cancer. It also has positive weight reducing effect on non-diabetic patient by improving insulin sensitivity (although the exact underlying pathomechanisms remain to be elucidated).

NCT ID: NCT05019989 Completed - Clinical trials for Breast Cancer Invasive

Trial of Diet, Physical Activity and Breast Cancer Recurrences: the DIANA-5 Study

Start date: June 1, 2008
Phase: N/A
Study type: Interventional

The investigators recruited 1542 Breast Cancer (BC) patients and to randomize the participants in two groups: 773 have received standard recommendations for healthy lifestyle without, however, any active support; 700 have received a combination of individual and group contacts over the course of one year, including kitchen courses, gym and dance classes, common meals and reinforcing meetings, with emphasis on a comprehensive dietary change including low saturated fat and low refined carbohydrates, and high whole grain cereals and pulses consumption. Compliance have been monitored through weight change and plasma glucose, triglycerides, cholesterol and testosterone. The main analysis will be by intention to treat. Under the hypothesis of reducing recurrence rate by 25% or 33% the statistical power of the study is 80% or, respectively, 90%, (P<0.05, 5-year follow-up).

NCT ID: NCT04980118 Completed - Breast Cancer Clinical Trials

A Nutritional Intervention and Physical Activity Program Reduce Body Weight in Women Newly Diagnosed With Breast Cancer.

Start date: April 2010
Phase: N/A
Study type: Interventional

To evaluate a nutritional intervention for women newly diagnosed with breast cancer on a weight control and physical activity program.

NCT ID: NCT04940026 Completed - Breast Cancer Clinical Trials

Study to Determine Absorption, Metabolism, and Excretion of [14C]-SAR439859, and to Assess Absolute Oral Bioavailability of Amcenestrant (SAR439859), in Healthy Post-menopausal Women

Start date: June 15, 2021
Phase: Phase 1
Study type: Interventional

Primary Objectives: - To assess the excretion balance after oral and IV administration of [14C]-SAR439859 - To assess PK of total radioactivity, [14C] -SAR439859 and its metabolite (M7) after IV administration of [14C]-SAR439859 and, PK of radioactivity, SAR439859 and M7 after oral administration of SAR439859 alone or with [14C]-SAR439859 - To assess IV clearance and absolute bioavailability of SAR439859 using microdose of [14C]-SAR439859 tracer on top of a single tablet oral dose. - To assess relative bioavailability of SAR439859 given as tablet or solution Secondary objectives: - To collect samples in order to assess metabolic profile in plasma and excreta of SAR439859 after oral administration of [14C]-SAR439859 as solution, contribution in plasma of SAR439859 and metabolite relative to total radioactivity and identify metabolites (samples will be analyzed according to metabolic analysis plan and results will be documented in a separate report). - To assess safety and tolerance of SAR439859

NCT ID: NCT04929964 Completed - Covid19 Clinical Trials

COVID-19 Pandemic: Effect on Management of Patients With Breast Cancer

Start date: January 1, 2020
Study type: Observational [Patient Registry]

The objective was to find out the impact of COVID-19 on stage of breast cancer at presentation and its effects on overall onco-surgical management. The investigator carried out this research to see the presenting stage of breast cancer in the participants in this pandemic and correlate its effect on stage of breast cancer and upstaging of disease

NCT ID: NCT04905667 Completed - Breast Cancer Clinical Trials

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

Start date: November 13, 2019
Phase: Phase 1
Study type: Interventional

This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.

NCT ID: NCT04894565 Completed - Breast Cancer Clinical Trials

Physiotherapy Program for Breast Cancer Women Following Surgery: A Pilot Clinical Trial

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

pilot study on physical therapy in women with breast cancer immediately following surgery

NCT ID: NCT04882371 Completed - Breast Cancer Clinical Trials

Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer

Start date: January 1, 2018
Study type: Observational

The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast cancer to neoadjuvant chemotherapy (NAC).